Literature DB >> 12466715

Acceptability of sexually transmitted infection screening among women in short-term substance abuse treatment.

Michelle A Lally1, Sara Alvarez, Ryan Macnevin, Carly Cenedella, Melissa Dispigno, Joseph I Harwell, David Pugatch, Timothy P Flanigan.   

Abstract

BACKGROUND: Substance abuse treatment centers provide an opportunity to offer sexually transmitted infection (STI) screening to a high-risk and hard-to-reach population. GOAL: The goal was to assess STI prevalence, risk factors, and acceptability of STI screening among females at substance abuse treatment centers with use of urine testing by ligase chain reaction and self-collected swab specimens. STUDY
DESIGN: Adult, female inpatients were offered free testing and treatment for chlamydia infection, gonorrhea, and trichomonas infection. Interviews were conducted to collect risk behavior data.
RESULTS: Eighty-six percent of inpatients (180/209) accepted testing. Twenty-three percent (41/177) had an STI. Of those with an STI, 90% (37/41) had trichomonas infection. All 41 infected patients received treatment. Drug use before sex, exchange of sex for money/drugs, and any gynecological complaint were significantly associated with infection. Most women were uninsured (76%). Only 45% had undergone a medical examination in the past year.
CONCLUSION: STI screening is highly acceptable among women in substance abuse treatment centers. Substance users are at high risk for STIs and may not otherwise receive medical care.

Entities:  

Mesh:

Year:  2002        PMID: 12466715     DOI: 10.1097/00007435-200212000-00003

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  8 in total

Review 1.  Behavior change and health-related interventions for heterosexual risk reduction among drug users.

Authors:  Salaam Semaan; Don C Des Jarlais; Rob Malow
Journal:  Subst Use Misuse       Date:  2006       Impact factor: 2.164

2.  Adoption and utilization of sexually transmitted infections testing in outpatient substance abuse treatment facilities serving high risk populations in the U.S.

Authors:  Erick G Guerrero; Julie A Cederbaum
Journal:  Int J Drug Policy       Date:  2010-10-20

3.  Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Lawrence S Brown; Steven Allan Kritz; R Jeffrey Goldsmith; Edmund J Bini; John Rotrosen; Sherryl Baker; Jim Robinson; Patrick McAuliffe
Journal:  J Subst Abuse Treat       Date:  2006-06

4.  A model to provide comprehensive testing for HIV, viral hepatitis, and sexually transmitted infections at a short-term drug treatment center.

Authors:  Michelle A Lally; Ryan MacNevin; Ziad Sergie; Robert Hitt; Melissa DiSpigno; Carly Cenedella; Michael D Stein
Journal:  AIDS Patient Care STDS       Date:  2005-05       Impact factor: 5.078

5.  Cannabis Use Disorders Predispose to the Development of Sexually Transmitted Diseases among Youth.

Authors:  Jack R Cornelius; Levent Kirisci; Duncan B Clark
Journal:  Int J Med Biol Front       Date:  2012

Review 6.  Traditional sexually transmitted disease prevention and control strategies: tailoring for African American communities.

Authors:  Roxanne Y Barrow; Cady Berkel; Lesley C Brooks; Samuel L Groseclose; David B Johnson; Jo A Valentine
Journal:  Sex Transm Dis       Date:  2008-12       Impact factor: 2.830

7.  From the NIH: proceedings of a workshop on the importance of self-obtained vaginal specimens for detection of sexually transmitted infections.

Authors:  Marcia M Hobbs; Barbara van der Pol; Patricia Totten; Charlotte A Gaydos; Anna Wald; Terri Warren; Rachel L Winer; Robert L Cook; Carolyn D Deal; M Elizabeth Rogers; Julius Schachter; King K Holmes; David H Martin
Journal:  Sex Transm Dis       Date:  2008-01       Impact factor: 2.830

8.  Drugs, alcohol and sexual health: opportunities to influence risk behaviour.

Authors:  Robert Patton; Francis Keaney; Michael Brady
Journal:  BMC Res Notes       Date:  2008-06-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.